Author:
Isaza Carlos,Henao Julieta,Martínez José H Isaza,Arias Juan C Sepúlveda,Beltrán Leonardo
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference36 articles.
1. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997, 37: 269-296. 10.1146/annurev.pharmtox.37.1.269.
2. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002, 41 (12): 913-958. 10.2165/00003088-200241120-00002.
3. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997, 283 (2): 434-442.
4. Brosen K, de Morais SM, Meyer UA, Goldstein JA: A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics. 1995, 5 (5): 312-317. 10.1097/00008571-199510000-00007.
5. Garcia-Barcelo M, Chow LY, Kum Chiu HF, Wing YK, Shing Lee DT, Lam KL, Waye MM: Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Clin Chem. 1999, 45 (12): 2273-2274.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献